We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.

Current Opportunities

San Francisco, CA
Closes: 16 Feb 2021 07:33
San Francisco, CA
Closes: 26 Jan 2021 12:50
This site is powered by SnapHire (www.snaphire.com)